Dr. Michael Morris on Combining and Sequencing Radium-223

Michael J. Morris, MD
Published: Friday, Nov 13, 2015

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Androgen receptor–directed therapy, chemotherapy, and novel therapeutics could also be combined with radium-223 to improve survival, says Morris. There is currently a study looking at radium-223 and abiraterone.

Work is also still being done to better understand how to administer radium-223 alone, says Morris. Questions still remain regarding how frequently patients should receive radium-223, how long they should take the drug, and at what dose.
 
Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses combining radium-223 with other types of treatment and how to best optimize the use of the drug alone.

Androgen receptor–directed therapy, chemotherapy, and novel therapeutics could also be combined with radium-223 to improve survival, says Morris. There is currently a study looking at radium-223 and abiraterone.

Work is also still being done to better understand how to administer radium-223 alone, says Morris. Questions still remain regarding how frequently patients should receive radium-223, how long they should take the drug, and at what dose.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x